

Dr. Kristof Vandekerckhove, MD
Medical Director and founder of Vista Alpina eye clinic



Training and professional background

- 2018 - 2022 President of the Tariff Commission / Board member, Swiss Society of Ophthalmology
- 2018 - Senior Advisor, Partners Group (Zug, Switzerland)
- 2008 - Founder, medical director, chief surgeon Vista Alpina eye center, Visp/Sierre/Sion, Switzerland
- 2005 - 2012 Training in ophthalmology and ophthalmic surgery: Lucerne cantonal eye clinic (PD I. Schipper), Inselspital Berne eye clinic (Prof. S. Wolf), Dr. Agarwal eye hospital (Chennai, India), Vista Alpina eye clinic (Switzerland)
- 2001 - 2005 Global Marketing Manager, and Global Medical Manager, Cardiovascular franchise, Novartis International, Basel, Switzerland and Tokyo, Japan
- 1999 - 2001 Medical advisor, Cardiovascular, Pfizer, Belgium
- 1998 - 2000 Master of Business Administration (executive MBA, Vlerick Leuven-Ghent Management School, Belgium)
- 1997 - 1999 Head of clinical studies, Therabel Pharma, Belgium
- 1997 - 1998 Master in pharmaceutical medicine, University of Brussels, Belgium
- 1996 - 1997 Cardiology, University Hospital "Jolimont", La Louvière, Belgium
- 1989 - 1996 Medical School, University of Gent, Belgium

Memberships

European Society of Cataract and Refractive Surgeons (ESCRS)
American Academy of Ophthalmology (AAO)
American Society of Cataract and Refractive Surgery (ASCRS)
Walliser Ärzteverband (WÄV) [Medical Association of canton VS]
Verbindung der Schweizer Ärztinnen und Ärzte (FMH) [Swiss Medical Association]
Schweizerische Ophthalmologische Gesellschaft (SOG) [Swiss Ophthalmology Association]
Swiss Alpine Club (SAC Zermatt)
Active member of several (sport and combat) shooting clubs in Switzerland

Awards

- 2014 Best of the Best Presentation at the ESCRS (European Society of Cataract and Refractive Surgery) September 17, 2014, London, UK.
K. Vandekerckhove.
Ankoris: a new toric IOL with insufficient rotational stability after cataract surgery
- 1995 Poster award at the symposium of the Belgian Association of Clinical Biology (first author): "De immuunstatus voor rubella en toxoplasma bij meisjes tussen 12 en 18 jaar"
- 1989 Winner of the Flemish Chemistry Olympics and participation in the international Chemistry Olympics in Halle, former GDR

Publications

- 2023 N. Tomagova, S. Elahi, **K. Vandekerckhove**. Clinical Outcomes of a New Non-Diffractive Extended Depth-of-Focus Intraocular Lens Targeted for Mini-Monovision. *Clinical Ophthalmology*, Dovepress. March 2023;17, 981-990
- 2018 **Vandekerckhove K.**, Refractive Surgery without a laser, *Cataract & Refractive Surgery Today*, 10/2018
- 2018 **Vandekerckhove K.**, Rotational Stability of Monofocal and Trifocal Intraocular Toric Lenses With Identical Design and Material but Different Surface Treatment, *International Ophthalmology*, *J Refract Surg*. 2018;34(2):84-91
- 2015 **Vandekerckhove K.**, Aflibercept versus ranibizumab for treating persistent diabetic macular oedema, *International Ophthalmology*, *Int Ophthalmol* 2015 Aug;35(4):603-9
- 2009 Lange AP, **Vandekerckhove K.**, Becht C, Zakrzewski PA, Schmid MK. Spontaneous closure of a traumatic macular hole. *Medical Ophthalmology Monthly* 2009 Apr; 226(4):359-60
- 2008 B. Kloeckener-Gruissem*, **K. Vandekerckhove*** et al (* first authors, equal contribution), Mutation of the solute carrier SLC16A12 associates with a novel syndrome combining autosomal dominant juvenile cataract with microcornea and glucosuria. *American Journal of Human Genetics* 2008 Mar;82(3):772-9.
- 2007 **Vandekerckhove K.**, Lange A. P., Herzog D. C. J., Schipper I., Juvenile cataract associated with micro-cornea and glucosuria: a new syndrome. *Medical Ophthalmology Monthly* 2007; 224:344-346
- 1998 R.A. Lefebvre and **K. Vandekerckhove**. Influence of nitroglycerine and long-term electrical stimulation on nitrergic relaxations in the pig gastric fundus, *British Journal of Pharmacology*, 123, 143-149, (1998).
- 1998 Ginsberg F., Joos E., Géczy J., Bruhwylter J., **Vandekerckhove K.** and Famaey JP. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia, *Journal of Musculoskeletal Pain*, 6(2), 5-17, (1998).

- 1998 Famaey J.P., **Vandekerckhove K.**, Géczy J. and Bruhwylér J. A large open-label trial of nimesulide in patients with osteoarticular conditions treated in a general practice setting, *Current therapeutic Research*, 59(7), 467-482, (1998).
- 1998 Famaey J.P., Bruhwylér J., Géczy J., **Vandekerckhove K.** and Appelboom T. Open controlled randomized multicenter comparison of nimesulide and diclofenac in the treatment of subacute and chronic low back pain, *Journal of Clinical Research*, 1, 219-238, (1998).
- 1997 Bruhwylér J., Monseu M-J., **Vandekerckhove K.** and Géczy J. Pirlindole, a reversible and specific monoamine oxidase A inhibitor: A retrospective evaluation of its clinical antidepressant profile, *European Journal of Clinical Research*, 9, 225-245, (1997).
- 1997 Braeckman J., Bruhwylér J., **Vandekerckhove K.** and Géczy J. Efficacy and safety of the extract of *Serenoa repens* in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms, *Phytotherapy Research*, Vol. 11, 558-563, (1997).
- 1996 **Vandekerckhove K.**, Verstraete A., Leroux-Roels G. Immunity against toxoplasma and rubella in girls between 12 and 18 years old. *Acta Clin. Belg.*, 1996 (abstract).
- 1996 **Vandekerckhove K.**, Verstraete A., Leroux-Roels G. De immuunstatus voor rubella en toxoplasma bij meisjes tussen 12 en 18 jaar. *Tijdschr. Geneesk.*, 1996; 52 : 319-323

Lectures and congress posters

Over 100 lectures and posters at congresses, domestic and abroad, for ophthalmologists, other physicians, opticians, pharmacists and patients.

Visp, 17 April 2023

